Navigation Links
BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
Date:8/22/2007

r cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: BioMarin's products and product candidates, commercialization of BioMarin's products; and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the commercialization of BioMarin's products; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2006 Annual Report on Form 10-K, as amended, and the factors contained in BioMarin's reports on Form 10-Q and Form 8-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R) and Naglazyme(R) are a registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Orapred(R) is a registered trademark of Medici
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GenTel licenses next generation cancer research
2. Third Wave licenses Innogenetics tech to settle lawsuit
3. WARF licenses patents for new glaucoma drug treatment
4. PKWARE Licenses Technology to Expand SecureZIP Standard
5. Mentor Licenses Botulinum From WARF and Plans Wisconsin Manufacturing Facility
6. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
7. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
8. Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep Technology
9. Novel MicroRNA Array Technology for Sensitive miRNA Profiling
10. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
11. Use of FlashPlate Technology for In Vitro Measurement of [35S]-GTPγS Binding in CHO Cells Expressing the Human 5-HT1B Receptor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... (PRWEB) September 18, 2014 Texas ... John Sharp, Texas A&M Health Science Center CEO ... Department of Health and Human Services (HHS), State ... a national pandemic influenza vaccine manufacturing facility in ... an anchor for the Texas A&M Biocorridor – ...
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global and Chinese Stem Cell Industry Report, 2014-2017" ... are undifferentiated biological cells that can differentiate into specialized ... stem cells. Stem cell therapy can be applied to ... system disease), nervous system diseases, damage or lesion of ...
(Date:9/18/2014)... Research and Markets has announced ... Report 2014" report to their offering. ... a professional and in-depth study on the current state ... report provides a basic overview of the industry including ... albumin market analysis is provided for the international markets ...
(Date:9/18/2014)... 18, 2014 Leatherwood Plastics has ... material, to stay competitive in the semiconductor, clean ... materials ultimately impact product quality and productivity, according ... , Established in 1980 in Lewisville, TX, ... fabricators have left the business. Much of Leatherwood’s ...
Breaking Biology Technology:Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2
... , BALTIMORE, Sept. 10 ... company whose personalized oncology services division assists physicians by providing ... a collaboration agreement with PinnacleCare , the ... world. , , PinnacleCare will offer Champions, ...
... , SAN DIEGO, Sept. 10 ... 2b clinical trial with Aeroquin((R)) (a novel aerosol formulation of ... that nebulized Aeroquin met the primary endpoint of reducing bacterial ... in sputum after 28 days of dosing versus placebo. ...
... , NEW HAVEN, Conn., Sept. ... a development-stage company focused on the discovery, development and ... care antibiotic-resistant infections, today announced that seven posters have ... on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in ...
Cached Biology Technology:Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 2Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 3Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 4Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients 2Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients 3Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients 4Rib-X Pharmaceuticals to Present at the 49th ICAAC 2Rib-X Pharmaceuticals to Present at the 49th ICAAC 3Rib-X Pharmaceuticals to Present at the 49th ICAAC 4
(Date:9/18/2014)... Clownfish spend their entire lives nestling in the protective ... as babies they sometimes travel hundreds of kilometres across ... by reef fish has been predicted, this is the ... between distant populations has been observed. , Dr Steve ... at the University of Exeter, and colleagues from the ...
(Date:9/17/2014)... Europaea started in 2000 as an EC-FP5 four-year project, ... of steady progress and successful participations in several EC ... Biodiversity Observation Network project (EU BON), to increase ... contributors and to extend the general dissemination of the ... has applied its novel e-Publishing tools to ...
(Date:9/17/2014)... (Hospital del Mar Medical Research Institute) and at the ... study in eLife showing that RNA called ... of new proteins, some of which could have important ... from the instructions found in an RNA molecule. However, ... information for the synthesis of proteins, meaning it is ...
Breaking Biology News(10 mins):Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Parts of genome without a known function may play a key role in the birth of new proteins 2
... evidence that Parkinson,s disease may have an infectious or ... is associated with late-onset sporadic Parkinson,s disease" appears online ... conducted by the NeuroGenetics Research Consortium, an international team ... the New York State Department of Health Wadsworth Center. ...
... State University have developed a method for predicting the ... the human body. Their work could have implications for ... of nanomaterials, as well as applications for drug delivery. ... Distinguished Professor of Pharmacology and director of the ...
... SALT LAKE CITY, July 26 Wall Street Communications ... Media, a world leader in content identification solutions, to ... a presence for the company in broadcast, government, and ... Media, based in Darmstadt, Germany, is a spinoff of ...
Cached Biology News:Researchers discover genetic link between immune system, Parkinson's disease 2Probing the nanoparticle: Predicting how nanoparticles will react in the human body 2Wall Street Communications Retained by iPharro Media 2
... stain has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... nucleic gel acid stain has also found ... bandshift assays. One mL stains 100 minigels. A ...
Synonym: modified Grace's Insect medium...
... acid synthetic peptide whose sequence is derived from bovine rhodopsin ... carboxy terminus): C - S(338) - K - T ... - A - P - A(348). This peptide ... polyclonal antibody that reacts with this product and bovine rhodopsin, ...
... The proteomic service includes protein ... analysis using the PDQuest software package ... MALDI-TOF mass spectrometry. In order to ... sample preparation, data analysis and format ...
Biology Products: